We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Hong Kong Reports Risk of Electric Shock With Medela Breast Pump

Hong Kong Reports Risk of Electric Shock With Medela Breast Pump

October 21, 2016

Hong Kong’s Department of Health issued a warning that Medela breast pumps with detachable power plugs have been associated with the risk of electrical shock.

The alert covers the UK (Type G) detachable power plugs of three models of Medela breast pumps.

The manufacturer is launching a voluntary replacement program for the detachable power plugs, which connect to a power supply base. Since June 2012, the manufacturer has marketed both breast pump systems and replacement power supplies (with enclosed plug adapters). The Medela breast pumps with affected detachable power plugs are Swing Maxi, Swing and Freestyle.

The voluntary replacement program only applies to detachable power plugs for UK sockets. Other products or power supply adapters for other sockets are not affected.

If users apply a certain level of force while removing affected detachable power plugs from UK sockets, the detachable power plugs might break apart potentially exposing live parts.

Compliance with IEC 62304 is required for all electromedical devices where basic safety or essential performance depends on software or firmware. However, many devicemakers — especially small to mid-size companies — are unaware that their devices must meet this standard. The confusion seems to stem from the fact that the guidance is called both “voluntary” and "mandatory." Clear up the confusion by purchasing a copy of FDAnews exclusive Device Software Safety Risks: Standards Lead to Closer FDA Scrutiny.

View today's stories

Medical Devices Inspections and Audits

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing